<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667251</url>
  </required_header>
  <id_info>
    <org_study_id>108919</org_study_id>
    <secondary_id>EGF108919</secondary_id>
    <secondary_id>CAN-NCIC-MA31</secondary_id>
    <secondary_id>2007-004568-27</secondary_id>
    <secondary_id>CDR0000594764</secondary_id>
    <nct_id>NCT00667251</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/Neu Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: HER2/neu is a receptor (protein) which is found in unusually high amounts in
      approximately 1 in 5 cancer patients. Scientific evidence suggests that having high amounts
      of the HER2/neu receptor is important for breast cancer to grow and spread. Women with
      previously untreated metastatic breast cancer (breast cancer that has spread to other organs)
      and with high levels of the HER2/neu receptor receive as their usual treatment chemotherapy
      with one of the approved chemotherapy drugs paclitaxel or docetaxel (called &quot;taxanes&quot;)
      together with another approved drug called &quot;trastuzumab&quot;. Chemotherapy drugs, such as
      paclitaxel and docetaxel, work either by killing tumour cells or by stopping them from
      dividing. Trastuzumab is an antibody that is given through a vein in the arm and it works by
      specifically &quot;targeting&quot; the HER2/neu i.e. it attaches to it and &quot;turns it off&quot;. Although
      some of the patients who receive this taxane plus trastuzumab treatment feel better for some
      months, the cancer usually starts to grow again. Lapatinib is a new drug. Like trastuzumab,
      it also works by specifically &quot;targeting&quot; the HER2/neu receptor, but it does so in a
      different way. Lapatinib is not an antibody. It is a pill that is taken daily by mouth.
      Because lapatinib works in a different way than trastuzumab, it may be worse, as good as or
      better than trastuzumab in keeping metastatic HER/neu positive cancer from growing. However,
      this is not known.

      Purpose: This randomized Phase III trial is comparing chemotherapy (a taxane) given together
      with lapatinib with chemotherapy (a taxane) given together with trastuzumab in women with
      HER2/neu positive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the progression-free survival of women with HER2/neu-positive metastatic
           breast cancer treated with taxane-based chemotherapy in combination with lapatinib
           ditosylate or trastuzumab (Herceptin®).

      Secondary

        -  To compare the overall survival.

        -  To compare the time to CNS metastases at the time of first progression.

        -  To compare the incidence rates of CNS metastases at the time of progression.

        -  To compare the overall objective response rate (complete or partial response), time to
           response, and duration of response in patients with measurable disease at baseline.

        -  To compare the clinical benefit response rate.

        -  To compare the adverse event profile.

        -  To compare the quality of life.

        -  To compare clinical outcomes using biomarker changes in biological samples.

        -  To compare health economics, including healthcare utilization and health utilities.

      OUTLINE: This is a multicenter study. Patients are stratified according to prior
      neoadjuvant/adjuvant anti-HER2/neu-targeted therapy (yes vs no), prior neoadjuvant/adjuvant
      taxane chemotherapy (yes vs no), planned taxane therapy (paclitaxel vs docetaxel), and liver
      metastasis (yes vs no). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive either paclitaxel IV on days 1, 8, and 15; treatment with
           paclitaxel repeats every 4 weeks for 6 courses in the absence of disease progression or
           unacceptable toxicity. Alternatively, patients may receive docetaxel IV on day 1;
           treatment with docetaxel repeats every 3 weeks for 8 courses in the absence of disease
           progression or unacceptable toxicity. Patients on docetaxel also receive filgrastim
           (G-CSF) according to institutional standard. All patients receive oral lapatinib
           ditosylate once daily during taxane treatment and continue after completion of taxane
           treatment, in the absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients receive paclitaxel IV on days 1, 8, and 15 and trastuzumab (Herceptin®)
           IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 6 courses in the
           absence of disease progression or unacceptable toxicity. Alternatively, patients may
           receive docetaxel IV and trastuzumab IV on day 1. Treatment repeats every 3 weeks for 8
           courses in the absence of disease progression or unacceptable toxicity. After completion
           of taxane chemotherapy and trastuzumab, all patients receive trastuzumab alone IV once
           every 3 weeks in the absence of disease progression or unacceptable toxicity.

      Formalin-fixed paraffin-embedded tissue samples are analyzed for ER, PgR, EGFR, CK5/6, Ki67,
      and other molecular biomarkers by tissue microarray and immunohistochemistry.

      Patients complete quality of life questionnaires (EORTC QLQ-C30 and a Trial Specific
      Checklist) at baseline, every 12 weeks for 96 weeks, and then every 24 weeks until disease
      progression.

      After completion of study treatment, patients are followed at 4 weeks post treatment, and
      then every 12 weeks thereafter (counting from the beginning of study therapy).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 7, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From randomization to RECIST V 1.0 progression or death assessed up to 39 months.</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization to death from any cause, assessed up to 44 months.</time_frame>
    <description>OS median follow-up not achieved; estimated with quartile estimates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CNS Metastases at the Time of First Progression</measure>
    <time_frame>From randomization to CNS metastases at time of first progression, assessed up to 39 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS Metastases at the Time of Progression (ITT)</measure>
    <time_frame>Incidence rate of CNS metastases at first progression assessed up to 39 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS Metastases at the Time of Progression (HER2+)</measure>
    <time_frame>Incidence rate of CNS mestastes at first progression, assessed up to 39 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Objective Response Rate (Complete or Partial) ITT</measure>
    <time_frame>4 years</time_frame>
    <description>Patients included in this assessment must have had at least one measurable lesion at baseline, and had at least one RECIST re-evaluation after baseline while on protocol therapy, prior to, or on, date of progression. Best overall response was classified to be Complete Response (CR) or Partial Response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Objective Response Rate (Complete or Partial) HER2/Neu+</measure>
    <time_frame>Median follow-up of 21.5 months.</time_frame>
    <description>Response determined by RECIST V 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Response Rate (ITT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Best overall response of CR, PR or stable disease at end of week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Response Rate (HER2/Neu+))</measure>
    <time_frame>24 weeks</time_frame>
    <description>Best overall response of CR, PR, or stable disease at end of week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the EORTC QLQ-C30 Global Score From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The global score ranges from 0-100, with higher values representing a better quality of life. At 12 weeks: Group mean difference between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Changes in Biomarkers on Clinical Outcomes</measure>
    <time_frame>Not available at this time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic Evaluation, Including Health Utilities, as Measured by the EQ-5D Questionnaire, and Healthcare Utilization</measure>
    <time_frame>Not available at this time</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">649</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plus taxane based chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plus taxane based chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).</description>
    <arm_group_label>Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).</description>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_label>Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).</description>
    <arm_group_label>Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.</description>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_label>Trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the breast

          -  Metastatic (stage IV) disease at primary diagnosis or at relapse after curative intent
             therapy

          -  Local or central laboratory confirmedHER2/neu* overexpressing and/or amplified disease
             in the invasive component of the primary or metastatic lesion as defined by the
             following:

               -  3+ overexpression (in &gt; 30% of invasive tumor cells) by immunohistochemistry
                  (IHC)

               -  2+ or 3+ overexpression (in ≤ 30% of invasive tumor cells) by IHC AND
                  demonstrates HER2/neu gene amplification by fluorescence in situ hybridization
                  (FISH) or chromogenic in situ hybridization (CISH)

               -  HER2/neu gene amplification by FISH/CISH (&gt; 6 HER2/neu gene copies per nucleus,
                  or a FISH/CISH ratio [HER2 gene copies to chromosome 17 signals] of ≥ 2.2) NOTE:
                  *Patients with a negative or equivocal overall result (FISH/CISH ratio of &lt; 2.2,
                  ≤ 6.0 HER2/neu gene copies per nucleus, or staining scores of 0, 1+, 2+, or 3+
                  [in ≤ 30% of neoplastic cells] by IHC) are not eligible

          -  Formalin-fixed paraffin-embedded tumor specimen available

          -  No CNS metastases (including leptomeningeal involvement)

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 6 months

          -  Absolute granulocyte count &gt; 1,500/mm³

          -  Platelet count &gt; 75,000/mm³

          -  Hemoglobin &gt; 10 g/dL

          -  Serum creatinine ≤ 2.0 times upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 times ULN (&lt; 3 times ULN for patients with Gilbert's disease)

          -  AST and/or ALT ≤ 2.5 times ULN (&lt; 5 times ULN for patients planning to receive
             paclitaxel-based therapy)

          -  LVEF ≥ 50% by MUGA or ECHO

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Must be accessible for study treatment and follow-up

          -  No history of other malignancies, except adequately treated ductal carcinoma in situ
             or lobular carcinoma in situ, adequately treated nonmelanoma skin cancer, curatively
             treated carcinoma in situ of the cervix, or other curatively treated solid tumor
             (non-breast) with no evidence of disease for ≥ 5 years

          -  No serious cardiac illness or condition including, but not limited to, any of the
             following:

               -  History of documented congestive heart failure

               -  Systolic dysfunction (LVEF &lt; 50%)

               -  High-risk uncontrolled arrhythmias (i.e., ventricular tachycardia, high-grade
                  atrioventricular block, or supraventricular arrhythmias that are not adequately
                  rate-controlled)

               -  Unstable angina pectoris requiring anti-anginal medication

               -  Clinically significant valvular heart disease

               -  Evidence of transmural infarction on ECG

               -  Inadequately controlled hypertension (i.e., systolic blood pressure [BP] &gt; 180 mm
                  Hg or diastolic BP &gt; 100 mm Hg)

               -  New York Heart Association class III-IV functional status

          -  No serious illness or medical condition that would not allow the patient to be managed
             according to the protocol including, but not limited to, any of the following:

               -  History of significant neurologic or psychiatric disorder that would impair the
                  ability to obtain informed consent or limit compliance with study requirements

               -  Active uncontrolled infection

               -  Serious or nonhealing wound, ulcer, or bone fracture

          -  No peripheral neuropathy ≥ grade 2

          -  No gastrointestinal (GI) tract disease resulting in an inability to take oral
             medication including, but not limited to, any of the following:

               -  Malabsorption syndrome

               -  Requirement for IV alimentation

               -  Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative
                  colitis)

          -  No history of allergic or hypersensitivity reactions to any study drug or their
             excipients or to compounds with similar chemical composition to any of the study drugs

               -  Prior allergic reactions to taxanes are allowed provided they were adequately
                  treated and, according to the treating physician, would not prohibit further
                  treatment with taxanes

        PRIOR CONCURRENT THERAPY:

          -  Recovered from all prior therapy

          -  No prior chemotherapy, immunotherapy, biological therapy, or anti-HER2/neu-targeted
             therapy for recurrent or metastatic breast cancer

          -  At least 12 months since prior chemotherapeutic agents, including taxanes, in the
             neoadjuvant or adjuvant setting

          -  At least 12 months since prior anti-HER2/neu-targeted therapy in the neoadjuvant or
             adjuvant setting

          -  Prior treatment with endocrine therapy in the neoadjuvant, adjuvant, or metastatic
             setting allowed

          -  At least 2 weeks since prior radiotherapy in the adjuvant or metastatic setting

               -  Prior radiotherapy to a solitary metastatic lesion allowed provided there is
                  documented disease progression after completion of radiotherapy

          -  More than 30 days (or 5 half-lives) since prior investigational drugs

          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors (6 months for
             amiodarone)

          -  At least 14 days since prior and no concurrent CYP3A4 inducers

          -  No prior surgical procedures affecting absorption (e.g., resection of stomach or small
             bowel)

          -  No concurrent palliative radiotherapy

          -  No other concurrent anticancer treatment

          -  No other concurrent investigational drugs for breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Highland</city>
        <state>California</state>
        <zip>92346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenwich</city>
        <state>Connecticut</state>
        <zip>06830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southington</city>
        <state>Connecticut</state>
        <zip>06489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902-3628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Post Falls</city>
        <state>Idaho</state>
        <zip>83854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kearney</city>
        <state>Nebraska</state>
        <zip>68845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kearney</city>
        <state>Nebraska</state>
        <zip>68847</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denville</city>
        <state>New Jersey</state>
        <zip>07834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parsippany</city>
        <state>New Jersey</state>
        <zip>07054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212-4772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sequim</city>
        <state>Washington</state>
        <zip>98382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1405CUB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1920CMK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cipolletti</city>
        <state>Río Negro</state>
        <zip>R8324EMB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viedma</city>
        <state>Río Negro</state>
        <zip>R8500ACE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes cedex</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70190</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coburg</city>
        <state>Bayern</state>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eggenfelden</city>
        <state>Bayern</state>
        <zip>84307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuerth</city>
        <state>Bayern</state>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosenheim</city>
        <state>Bayern</state>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weiden</city>
        <state>Bayern</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuerstenwalde</city>
        <state>Brandenburg</state>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lich</city>
        <state>Hessen</state>
        <zip>35423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goslar</city>
        <state>Niedersachsen</state>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leer</city>
        <state>Niedersachsen</state>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coesfeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porta Westfalica</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Troisdorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53840</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Velbert</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koblenz</city>
        <state>Rheinland-Pfalz</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saarbruecken</city>
        <state>Saarland</state>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poriya</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano (pn)</city>
        <state>Friuli-Venezia-Giulia</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sora (FR)</city>
        <state>Lazio</state>
        <zip>03039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lecce</city>
        <state>Puglia</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prato (PO)</city>
        <state>Toscana</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama</city>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songpa-gu, Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62450</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Obregon</city>
        <state>Sonora</state>
        <zip>85000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico City</city>
        <zip>CP 14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-226</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plock</city>
        <zip>09-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kirov</city>
        <zip>610021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lipetsk</city>
        <zip>398005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115 478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavropol</city>
        <zip>355047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ufa,</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elche</city>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozuelo De Alarcon (Madrid)</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan County</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiangmai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelmsford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cheltenham</city>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colchester</city>
        <zip>CO3 3NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cottingham, Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrogate</city>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huddersfield</city>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poole, Dorset</city>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Whitchurch, Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>September 24, 2013</results_first_submitted>
  <results_first_submitted_qc>June 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2014</results_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lapatinib</title>
          <description>Lapatinib - 1250 mg po daily Taxane based chemotherapy: Paclitaxel - 80 mg/m2 IV q weekly (days 1, 8 and 15 of a 4-week cycle) or Docetaxel - 75 mg/m2 IV q 3 weekly (day 1 of a 3-week cycle) plus G-CSF - according to institutional standards. Followed by: Lapatinib - 1500 mg po daily until disease progression.</description>
        </group>
        <group group_id="P2">
          <title>Trastuzumab</title>
          <description>Trastuzumab ng- IV weekly (loading dose 4 mg/kg, subsequent doses 2 mg/kg) Paclitaxel - 80 mg/m2 IV weekly (days 1, 8 and 15 of a 4-week cycle). or Trastuzumab - IV weekly (loading dose 8 mg/kg, subsequent doses 6 mg/kg) Docetaxel - 75 mg/m2 IV q 3 weekly (day 1 of a 3 week cycle) Followed by: Trastuzumab - 6 mg/kg IV q 3 weekly until disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="326"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Combination Rx</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Monotherapy</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Started</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other/missing</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptomatic progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lapatinib</title>
        </group>
        <group group_id="B2">
          <title>Trastuzumab</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="326"/>
            <count group_id="B2" value="326"/>
            <count group_id="B3" value="652"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="523"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="26.6-87.1" lower_limit="26.6" upper_limit="87.1"/>
                    <measurement group_id="B2" value="54.4" spread="29.3-84.3" lower_limit="29.3" upper_limit="84.3"/>
                    <measurement group_id="B3" value="54.9" lower_limit="26.6" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="326"/>
                    <measurement group_id="B3" value="652"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="571"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="480"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Country</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance Status</title>
          <description>Grade 0= Fully active, able to carry on all pre-disease performance without restriction. Grade 1= Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. Grade 2= Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours Grade 3= Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours. Grade 4= Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair. Grade 5= Dead</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior (Neo) Adjuvant Anti-HER2/neu Targeted Therapy</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior (Neo) Adjuvant Taxane Chemotherapy</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior (Neo) Adjuvant Anthracyclines</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior (Neo) Adjuvant Other Chemotherapy</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primary Diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic Relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior (Neo) Adjuvant/Metastatic Endocrine Therapy</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior (Neo) Adjuvant/Metastatic Radiotherapy</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned Taxane Therapy</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Weekly Paclitaxel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Weekly Docetaxel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior (Neo) Adjuvant Other Therapy</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="321"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver Metastasis</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Review HER2/Neu Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive IHC or FISH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative IHC and FISH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Equivocal IHC and FISH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Review ER Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive (&gt;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Review PR Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive (&gt;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Review ki67</title>
          <units>% cells positive</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.33" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="B2" value="31.43" lower_limit="0" upper_limit="90"/>
                    <measurement group_id="B3" value="32.37" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Review CK5 Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive (&gt;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Review EGFR Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive (&gt;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>From randomization to RECIST V 1.0 progression or death assessed up to 39 months.</time_frame>
        <population>two subpopulations: ITT (n=652) and HER2+ (n=537)</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>two subpopulations: ITT (n=652) and HER2+ (n=537)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT n=326, 326</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" lower_limit="0.0" upper_limit="32.69"/>
                    <measurement group_id="O2" value="11.30" lower_limit="0.0" upper_limit="38.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2+n=270, 267</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" lower_limit="0.0" upper_limit="32.69"/>
                    <measurement group_id="O2" value="13.63" lower_limit="0.0" upper_limit="38.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>OS median follow-up not achieved; estimated with quartile estimates</description>
        <time_frame>From randomization to death from any cause, assessed up to 44 months.</time_frame>
        <population>two subpopulations: ITT (n=652) and HER2+ (n=537)</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>OS median follow-up not achieved; estimated with quartile estimates</description>
          <population>two subpopulations: ITT (n=652) and HER2+ (n=537)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="14.2" upper_limit="31.3"/>
                    <measurement group_id="O2" value="21.8" lower_limit="14.3" upper_limit="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CNS Metastases at the Time of First Progression</title>
        <time_frame>From randomization to CNS metastases at time of first progression, assessed up to 39 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CNS Metastases at the Time of First Progression</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT n=326, 326</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" lower_limit="0.0" upper_limit="32.69"/>
                    <measurement group_id="O2" value="11.10" lower_limit="0.0" upper_limit="38.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2+n=270, 267</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" lower_limit="0.0" upper_limit="32.69"/>
                    <measurement group_id="O2" value="13.17" lower_limit="0.0" upper_limit="38.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CNS Metastases at the Time of Progression (ITT)</title>
        <time_frame>Incidence rate of CNS metastases at first progression assessed up to 39 months</time_frame>
        <population>178 Lapatinib patients with metastases assessed for CNS metastases; 157 Trastuzumab patients with metastases assessed for CNS metastases.</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>CNS Metastases at the Time of Progression (ITT)</title>
          <population>178 Lapatinib patients with metastases assessed for CNS metastases; 157 Trastuzumab patients with metastases assessed for CNS metastases.</population>
          <units>CNS metastases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CNS Metastases at the Time of Progression (HER2+)</title>
        <time_frame>Incidence rate of CNS mestastes at first progression, assessed up to 39 months</time_frame>
        <population>151 patients with metastases assessed for CNS metastases; 128 patients with metastases assessed for CNS metastases.</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>CNS Metastases at the Time of Progression (HER2+)</title>
          <population>151 patients with metastases assessed for CNS metastases; 128 patients with metastases assessed for CNS metastases.</population>
          <units>CNS metastases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Objective Response Rate (Complete or Partial) ITT</title>
        <description>Patients included in this assessment must have had at least one measurable lesion at baseline, and had at least one RECIST re-evaluation after baseline while on protocol therapy, prior to, or on, date of progression. Best overall response was classified to be Complete Response (CR) or Partial Response (PR).</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response Rate (Complete or Partial) ITT</title>
          <description>Patients included in this assessment must have had at least one measurable lesion at baseline, and had at least one RECIST re-evaluation after baseline while on protocol therapy, prior to, or on, date of progression. Best overall response was classified to be Complete Response (CR) or Partial Response (PR).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Objective Response Rate (Complete or Partial) HER2/Neu+</title>
        <description>Response determined by RECIST V 1.0</description>
        <time_frame>Median follow-up of 21.5 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response Rate (Complete or Partial) HER2/Neu+</title>
          <description>Response determined by RECIST V 1.0</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Response Rate (ITT)</title>
        <description>Best overall response of CR, PR or stable disease at end of week 24.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Response Rate (ITT)</title>
          <description>Best overall response of CR, PR or stable disease at end of week 24.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Response Rate (HER2/Neu+))</title>
        <description>Best overall response of CR, PR, or stable disease at end of week 24.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Response Rate (HER2/Neu+))</title>
          <description>Best overall response of CR, PR, or stable disease at end of week 24.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the EORTC QLQ-C30 Global Score From Baseline to 12 Weeks</title>
        <description>The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The global score ranges from 0-100, with higher values representing a better quality of life. At 12 weeks: Group mean difference between arms</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Plus taxane based chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab</title>
            <description>Plus taxane based chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the EORTC QLQ-C30 Global Score From Baseline to 12 Weeks</title>
          <description>The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The global score ranges from 0-100, with higher values representing a better quality of life. At 12 weeks: Group mean difference between arms</description>
          <units>Score on global scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.67" spread="20.93"/>
                    <measurement group_id="O2" value="64.41" spread="20.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Changes in Biomarkers on Clinical Outcomes</title>
        <time_frame>Not available at this time</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Economic Evaluation, Including Health Utilities, as Measured by the EQ-5D Questionnaire, and Healthcare Utilization</title>
        <time_frame>Not available at this time</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Median follow-up of 21.5 months</time_frame>
      <desc>Serious Adverse Events that were reported to Health Canada</desc>
      <group_list>
        <group group_id="E1">
          <title>Lapatinib</title>
          <description>Plus taxane based chemotherapy</description>
        </group>
        <group group_id="E2">
          <title>Trastuzumab</title>
          <description>Plus taxane based chemotherapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="322" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage pulmonary - Nose</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary - Nose</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Watery Eye</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Watery Eye</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="254" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Distention</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemmorroids</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam)</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain Abdomen NOS</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - stomach</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - throat/pharynx/larynx</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam)-oral cavity</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain Abdomen NOS</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Flu-like Syndrome</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Flu-like Syndrome</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Delayed Therapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infections with normal ANC Ungual</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infections with normal ANC Upper Airway NOS</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infections with normal ANC Ungual</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infections with normal ANC Upper Airway NOS</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - back</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - bone</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - chest/thorax NOS</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - extremity limb</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - back</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - bone</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - extremity limb</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain - tumour pain</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - headache</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain - headache</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <description>Delayed Therapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration - Anxiety</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Anxiety</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - breast</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nasal - paranasal reactions</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nasal - paranasal reactions</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Puritis</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <description>Acute Period - Combination Therapy &gt;= 5% on at least one arm</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Puritis</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Acute Period - Monotherapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>Delayed Therapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <description>Delayed Therapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Delayed Therapy &gt;=5% on at least 1 arm</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="322"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

